Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000231 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00000231 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA).
The verdict
NCT00000231, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
Interventions
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000231
The ClinicalTrials.gov registry entry for NCT00000231 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000231 about?
NCT00000231 is a clinical study titled "Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13". The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
What is the current status of trial NCT00000231?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-02.
What interventions are being tested in trial NCT00000231?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000231?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.